Related references
Note: Only part of the references are listed.Health State Values for Use in the Economic Evaluation of Treatments for Alzheimer's Disease
James Shearer et al.
DRUGS & AGING (2012)
Net costs of dementia by disease stage
H. Leicht et al.
ACTA PSYCHIATRICA SCANDINAVICA (2011)
Costs of Care for Dementia Patients in Community Setting: An Analysis for Mild and Moderate Disease Stage
Larissa Schwarzkopf et al.
VALUE IN HEALTH (2011)
Cost of Illness in Alzheimer's Disease
Peter Kiencke et al.
MEDIZINISCHE KLINIK (2010)
Cost Effectiveness of Donepezil in the Treatment of Mild to Moderate Alzheimer's Disease A UK Evaluation Using Discrete-Event Simulation
Denis Getsios et al.
PHARMACOECONOMICS (2010)
Discrete Event Simulation: The Preferred Technique for Health Economic Evaluations?
Jaime J. Caro et al.
VALUE IN HEALTH (2010)
Prevalence and Incidence of Dementia in Germany - A Study Based on Data from the Public Sick Funds in 2002
U. Ziegler et al.
GESUNDHEITSWESEN (2009)
Decision analytic models for Alzheimer's disease: State of the art and future directions
Joshua T. Cohen et al.
ALZHEIMERS & DEMENTIA (2008)
Treatment of a whole population sample of Alzheimer's disease with donepezil over a 4-year period: Lessons learned
Sarah Lyle et al.
DEMENTIA AND GERIATRIC COGNITIVE DISORDERS (2008)
Systematic review of economic evaluations of Alzheimer’s disease medications
Mark Oremus
Expert Review of Pharmacoeconomics & Outcomes Research (2008)
Survival times in people with dementia: analysis from population based cohort study with 14 year follow-up
Jing Xie et al.
BMJ-BRITISH MEDICAL JOURNAL (2008)
Long-term cost-effectiveness of donepezil for the treatment of Alzheimer's disease
Stefan J. Teipel et al.
EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE (2007)
Donepezil preserves cognition and global function in patients with severe Alzheimer disease
S. E. Black et al.
NEUROLOGY (2007)
Emerging methods in economic modeling of imaging costs and outcomes: A short report on discrete event simulation
William Hollingworth et al.
ACADEMIC RADIOLOGY (2007)
Predictive validity of neuropsychiatric subgroups on nursing home placement and survival in patients with Alzheimer disease
Saw-Myo Tun et al.
AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY (2007)
Recommendations for the diagnosis and management of Alzheimer's disease and other disorders associated with dementia: EFNS guideline
G. Waldemar et al.
EUROPEAN JOURNAL OF NEUROLOGY (2007)
Modelling disease progression in Alzheimer's disease - A review of modelling methods used for cost-effectiveness analysis
Colin Green
PHARMACOECONOMICS (2007)
Donepezil in patients with severe Alzheimer's disease:: double-blind, parallel-group, placebo-controlled study
B Winblad et al.
LANCET (2006)
Cholinesterase inhibitors for Alzheimer's disease
J Birks
COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2006)
3-year study of donepezil therapy in Alzheimer's disease: Effects of early and continuous therapy
B. Winblad et al.
DEMENTIA AND GERIATRIC COGNITIVE DISORDERS (2006)
Modelling the cost effectiveness of cholinesterase inhibitors in the management of mild to moderately severe Alzheimer's disease
N Bosanquet et al.
PHARMACOECONOMICS (2006)
Modelling the cost effectiveness of cholinesterase inhibitors in the management of mild to moderately severe Alzheimer's disease
C Green et al.
PHARMACOECONOMICS (2005)
Drug therapy - Alzheimer's disease
JL Cummings
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Donepezil for the treatment of mild to moderate Alzheimer's disease in France: The economic implications
F Fagnani et al.
DEMENTIA AND GERIATRIC COGNITIVE DISORDERS (2004)
An economic evaluation of donepezil in mild to moderate Alzheimer's disease: Results of a 1-year, double-blind, randomized trial
A Wimo et al.
DEMENTIA AND GERIATRIC COGNITIVE DISORDERS (2003)
Economic evaluation of donepezil treatment for Alzheimer's disease in Japan
S Ikeda et al.
DEMENTIA AND GERIATRIC COGNITIVE DISORDERS (2002)
A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease
H Feldman et al.
NEUROLOGY (2001)
A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients
RC Mohs et al.
NEUROLOGY (2001)
A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD
B Winblad et al.
NEUROLOGY (2001)
Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease
RS Doody et al.
ARCHIVES OF NEUROLOGY (2001)
Share Paper
